Through a comprehensive multi-omics strategy, we systematically characterized the biological and clinical significance of MUCL1+CD24+ cells in breast cancer, and we used multiplex immunohistochemistry to confirm the poor role of MUCL1+CD24+ cells. This evidence concerns the gene MUCL1 and breast cancer.